Spot­light­ing sub­group analy­sis, Ther­a­vance tries to carve out 'nar­row, but crit­i­cal­ly im­por­tan­t' mar­ket for failed drug

When Ther­a­vance Bio­phar­ma re­vealed last Sep­tem­ber that its first Phase III tri­al for am­prelox­e­tine had end­ed in fail­ure, it de­mot­ed the drug from lead sta­tus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.